Altria 2Q Profit Falls on Softer Oral-Tobacco Performance
By Katherine Hamilton
Altria Group had virtually flat revenue and lower profit in the second quarter, as lower sales of its nicotine pouches offset some of the growth in its cigarettes business.
The tobacco company on Thursday posted a profit of $2.3 billion, or $1.37 a share, compared with $2.38 billion, or $1.41 a share, a year earlier.
Stripping out certain one-time items, adjusted per-share earnings were $1.48, behind the $1.50 anticipated by analysts, according to FactSet.
Revenue was roughly flat at $6.11 billion. Analysts surveyed by FactSet forecast revenue of $5.35 billion.
Within smokeable products, which includes Marlboro and Virginia Slims cigarettes, revenue increased 0.7%. That growth was driven by higher pricing and offset partially by more promotions and lower shipment volume.
Revenue from the company's oral-tobacco business, which includes on! nicotine pouches, fell 5.3%.
Altria narrowed its full-year guidance for adjusted earnings per share to a range of $5.61 to $5.72, from a previous range of $5.56 to $5.72.
The narrowed outlook reflects Altria's expectation that it will get a greater benefit from cigarette import and export activity in the second half of the year compared with the first.
Shares were down 3.4% to $72.40 in premarket trading Thursday.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
July 30, 2026 07:42 ET (11:42 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
